With $123M to invest, Kos aims to build bridge to Greek biotech ecosystem

Kos co-founder Simos Simeonidis aims to use the investment firm to connect Western entrepreneurship with Greece’s scientific talent pool, with the long-term goal of building a biotech ecosystem in the Southeastern European country.

This month, Kos Biotechnology Partners announced the third closing of its first fund, now with $123 million to support private biopharmas, pharma services companies, and adjacent technology start-ups. Simeonidis said the firm is already the largest VC in Greece, and its fund is the first focused on life sciences in that country...